Alvotech (NASDAQ:ALVOW – Get Free Report) was the recipient of a large growth in short interest during the month of February. As of February 28th, there was short interest totalling 9,400 shares, a ...

Celltrion today announced the U.S. launch of STEQEYMA��(ustekinumab-stba), a biosimilar to STELARA� (ustekinumab), following approval by the U.S. Food and Drug Administration (FDA) in December 2024.

Barclays 27th Annual Global Healthcare Conference Call March 12, 2025 2:00 PM ETCompany ParticipantsBrian Evanko - Chief ...

The arrival of biosimilars like Celltrion's STEQEYMA and Biocon's YESINTEK is shaking up the psoriatic arthritis market, challenging blockbuster biologics with cost-effective alternatives. As ...

Biosimilars can not only reduce patients' financial burdens, but also encourage more people to go for early diagnosis and ...

Samsung Bioepis Co. and Celltrion Inc. are outpacing long-established global drug manufacturers such as Amgen Inc. and Sandoz ...

Since the FDA’s groundbreaking approval of Zarxio in 2015, the US biosimilars market has surged to 67 approvals across 18 ...

In a cohort of more than 11,000 patients from the U.K. and Ireland, a comparable proportion of new adalimumab users achieved ...

It has been 10 years since the first biosimilar was approved by the FDA. The grades on how the market for biosimilars has ...

Looking ahead to 2025, Sandoz said it expects net sales to grow by a mid-single digit percentage in constant currencies.